Last updated: March 4, 2026
What are the key excipient components of Harris Teeter Mucus Relief D?
Harris Teeter Mucus Relief D contains the following primary active ingredients:
- Pseudoephedrine Hydrochloride (60 mg): decongestant
- Guaifenesin (200 mg): expectorant
Its excipient profile typically includes:
- Microcrystalline cellulose: diluent and binder
- Lactose monohydrate: filler
- Croscarmellose sodium: disintegrant
- Magnesium stearate: lubricant
- Silicon dioxide: glidant
The specific formulation can vary, but these excipients are common in marketed oral tablets for cold relief.
How does excipient choice affect drug stability, efficacy, and manufacturing?
Stability
Excipients like lactose and microcrystalline cellulose confer stability by maintaining tablet integrity and preventing moisture ingress. Magnesium stearate promotes uniform mixing and prevents caking.
Efficacy
Disintegrants such as croscarmellose sodium facilitate rapid disintegration, optimizing drug release. The choice of excipients influences dissolution rates and bioavailability.
Manufacturing
The excipient profile impacts flowability, compressibility, and production scale-up. For instance, lactose and microcrystalline cellulose improve compressibility, enabling consistent tablet formation.
What are current trends in excipient strategy for OTC cold medications?
- Enhanced solubility: Use of disintegrants and glidants to improve dissolution.
- Taste masking: Incorporation of flavoring agents and sweeteners.
- Reduced excipient load: Minimize non-essential excipients to reduce allergy risks.
- Sustainability: Preference for excipients from renewable sources or with lower environmental impact.
What commercial opportunities exist in excipient development?
Differentiation through formulation innovation
- Developing pediatric or ultra-fast dissolving formulations with novel excipients, like certain disintegrants or taste-masking agents.
- Creating formulations with reduced excipient content reducing allergenicity.
Market expansion via patent protection
- Innovation in excipient combinations can generate patent barriers, enabling premium pricing.
- Patentable excipient combinations can secure competitive advantage.
Regulatory advantages
- Use of GRAS (Generally Recognized As Safe) excipients streamlines approval.
- Novel excipients approved through filing pathways (e.g., FDA’s New Dietary Ingredient process) can open pathways to new formulations.
Supply chain considerations
- Sourcing high-quality excipients reliably to meet demand peaks.
- Developing proprietary excipient formulations to lock out competition.
Summary of key excipient options for commercial focus
| Strategy |
Examples |
Potential Impact |
| Formulation innovation |
Ultra-fast dissolving tablets, taste masking |
Market differentiation, patent potential |
| Use of novel excipients |
Crospovidone, α-cyclodextrin |
Enhanced bioavailability, stability |
| Reduced excipient load |
Minimalist formulations |
Safety profile, allergen reduction |
| Sustainability-focused excipients |
Plant-based fillers, biodegradable binders |
Market appeal, regulatory advantage |
Regulatory landscape influencing excipient use
- FDA guidance emphasizes safety and compatibility.
- EMA evaluates excipient safety within the context of target populations.
- Approvals for novel excipients require robust safety data, offering potential barriers but also opportunities to establish market exclusivity.
Key Takeaways
- Excipient choice in Harris Teeter Mucus Relief D affects stability, efficacy, and manufacturing efficiency.
- Trends favor minimally invasive, fast-dissolving, and taste-masked formulations.
- Innovation in excipients provides avenues for patent protection, product differentiation, and premium pricing.
- Regulatory strategies favor GRAS excipients, but novel excipients can open new formulations.
- Supply chain stability of high-quality excipients supports commercialization efforts.
FAQs
Q1. Can new excipients improve the efficacy of OTC cold medications?
Yes. New excipients can enhance disintegration, dissolution, and stability, leading to faster relief and better patient experience.
Q2. What are risks associated with excipient reformulation?
Introducing novel excipients may face regulatory hurdles and require extensive safety data. Consumer acceptance of new ingredients can also influence market success.
Q3. How does excipient selection impact patentability?
Unique combinations or novel excipients can be patented, providing a competitive edge and potential for extended exclusivity.
Q4. Are there sustainability considerations in excipient selection?
Yes. Use of renewable, biodegradable, and environmentally friendly excipients aligns with regulatory trends and consumer preferences.
Q5. What regulatory pathways support innovation in excipients?
FDA’s Generally Recognized As Safe (GRAS) list facilitates use of common excipients, while new excipients can be approved through Investigational New Drug (IND) pathways or equivalent.
[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Drug Products.
